MADHAVBAUG (MADHAVBAUG) fundamentals

MADHAVBAUG is a listed company, part of the Healthcare Services sector, listed on the NSE as MADHAVBAUG (ISIN INE0JR301013). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.

What MADHAVBAUG does

Vaidya Sane Ayurved Laboratories Limited is an India-based company, which is engaged in research and development in ayurvedic medicines and the sale of ayurvedic medicines and products through its various franchises and own clinics. The Company is also involved in providing ayurved medical professional services across its various clinics, including panchkarma and other ayurvedic treatments through the running of ayurvedic hospitals. The Company operates under brand Madhavbaug. It uses diagnostics, diet, physiotherapy and ayurveda to provide heart disease, diabetes, hypertension and obesity reversal treatments to its patients. The Company operates approximately 360 clinics across Maharashtra, Madhya Pradesh, Gujarat, Uttar Pradesh, Goa, Karnataka, Delhi, Punjab, Uttarakhand, West Bengal, and Chhattisgarh. The Company operates three cardiac prevention and rehabilitation hospitals in Khopoli, Kondhali, and Vishakhapatnam.

Valuation and market data

Last close₹160.00
Market capitalisation₹169 crore
Enterprise value₹170 crore
P/E (TTM)0.00
Price to book2.71
Price to sales (TTM)0.00
Book value per share₹59.13
Dividend yield0.00%
SectorHealthcare Services
Industry

Annual results

PeriodRevenueProfit before taxNet profitEPS
Mar 2026₹109 crore₹11 crore₹9 crore0.00
Mar 2025₹92 crore₹10 crore₹7 crore6.76
Mar 2024₹101 crore₹3 crore₹2 crore2.02
Mar 2023₹101 crore₹6 crore₹5 crore4.60

Figures are as reported (consolidated), in ₹ crore.

Shareholding pattern

As of Mar 2026:

Promoters66.3%
Foreign institutions (FII)0.0%
Mutual funds0.0%
Other domestic institutions0.0%
Retail and others33.7%

More on BreakPoint

FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.

Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.